Published in Eur J Cancer Prev on May 01, 2010
Predictors of sun protection behaviors and severe sunburn in an international online study. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Linguistic acculturation and skin cancer-related behaviors among Hispanics in the southern and western United States. JAMA Dermatol (2013) 0.98
Ion channels expression and function are strongly modified in solid tumors and vascular malformations. J Transl Med (2016) 0.96
Skin cancer surveillance behaviors among US Hispanic adults. J Am Acad Dermatol (2012) 0.93
Predicting sun protection behaviors using protection motivation variables. J Behav Med (2013) 0.83
Psychosocial correlates of sunburn among young adult women. Int J Environ Res Public Health (2012) 0.82
Skin examination behavior: the role of melanoma history, skin type, psychosocial factors, and region of residence in determining clinical and self-conducted skin examination. Arch Dermatol (2012) 0.78
Psychosocial Predictors for Cancer Prevention Behaviors in Workplace Using Protection Motivation Theory. Adv Prev Med (2015) 0.78
PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach. Oncotarget (2016) 0.75
A Qualitative Study of Quality of Life Concerns following a Melanoma Diagnosis. J Skin Cancer (2017) 0.75
Red meat and fruit intake is prognostic among patients with localized cutaneous melanomas more than 1mm thick. Cancer Epidemiol (2014) 0.75
The Health Belief Model: a decade later. Health Educ Q (1984) 25.48
The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol (1988) 9.51
Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol (2004) 5.49
The epidemiology of UV induced skin cancer. J Photochem Photobiol B (2001) 5.05
Genetic risk and behavioural change. BMJ (2001) 2.64
Reproducibility of self-reported melanoma risk factors in a large cohort study of Norwegian women. Melanoma Res (2008) 2.32
Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol (2009) 2.32
Multiple skin cancer risk behaviors in the U.S. population. Am J Prev Med (2008) 1.88
Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE). Int J Cancer (1995) 1.68
Effects of UV photographs, photoaging information, and use of sunless tanning lotion on sun protection behaviors. Arch Dermatol (2005) 1.58
A randomized controlled trial of an appearance-focused intervention to prevent skin cancer. Cancer (2008) 1.55
A psychosocial model of sun protection and sunbathing in young women: the impact of health beliefs, attitudes, norms, and self-efficacy for sun protection. Health Psychol (2000) 1.52
Examination of the efficacy of an appearance-focused intervention to reduce UV exposure. J Behav Med (2002) 1.45
Primary prevention of skin cancer: a review of sun protection in Australia and internationally. Health Promot Int (2004) 1.37
Long-term effects of appearance-based interventions on sun protection behaviors. Health Psychol (2007) 1.29
Application of Azjen's theory of planned behavior to predict sunbathing, tanning salon use, and sunscreen use intentions and behaviors. J Behav Med (1997) 1.27
Changing knowledge and attitudes about skin cancer risk factors in adolescents. Health Psychol (1992) 1.23
Tanning habits and sunburn in a Swedish population age 13-50 years. Eur J Cancer (2001) 1.23
Attitudes, subjective norms and perception of behavioural control as predictors of sun-related behaviour in Swedish adults. Prev Med (2004) 1.16
The impact of an appearance-based educational intervention on adolescent intention to use sunscreen. Health Educ Res (2007) 1.14
Stability of questionnaire items measuring behaviours, attitudes and stages of change related to sun exposure. Melanoma Res (2002) 1.13
Predictors of Norwegian adolescents' sunbathing and use of sunscreen. Health Psychol (1994) 1.11
Predictors of sunbathing and sunscreen use in college undergraduates. J Behav Med (1996) 1.08
Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol (1991) 1.02
Tanning and cutaneous malignancy. Dermatol Surg (2008) 1.01
Sunbathing habits and sunscreen use among white adults: results of a national survey. Am J Public Health (1997) 1.00
Sunbathing and sunbed use related to self-image in a randomized sample of Swedish adolescents. Eur J Cancer Prev (1998) 0.97
Ten-year changes in sun protection behaviors and beliefs of young adults in 13 European countries. Prev Med (2006) 0.95
The Queensland Cancer Risk Study: behavioural risk factor results. Aust N Z J Public Health (2006) 0.93
What do young people think about the dangers of sunbathing, skin cancer and sunbeds? A questionnaire survey among Italians. Photodermatol Photoimmunol Photomed (2000) 0.91
Sunbathing and sun-protection behaviors and attitudes of young Swedish adults with hereditary risk for malignant melanoma. Cancer Nurs (2001) 0.89
Beliefs, knowledge and attitudes as predictors of sunbathing habits and use of sun protection among Swedish adolescents. Eur J Cancer Prev (2001) 0.89
What influences university students' intentions to practice safe sun exposure behaviors? J Adolesc Health (2004) 0.88
The genetics of susceptibility to cutaneous melanoma. Drugs Today (Barc) (2005) 0.87
Sunbathing: college students' knowledge, attitudes, and perceptions of risks. J Am Coll Health (1993) 0.87
The psychology of sun-exposure and tanning. Clin Dermatol (1998) 0.84
Public knowledge about characteristics of moles and melanomas. Aust J Public Health (1992) 0.80
Skin cancer attitudes: a cross-national comparison. Br J Soc Psychol (1995) 0.77
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med (2014) 10.38
High frequency of BRAF mutations in nevi. Nat Genet (2002) 9.95
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
A versatile gene-based test for genome-wide association studies. Am J Hum Genet (2010) 8.44
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
TERT promoter mutations in familial and sporadic melanoma. Science (2013) 7.82
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell (2004) 6.08
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
A genome-wide association study identifies novel alleles associated with hair color and skin pigmentation. PLoS Genet (2008) 4.57
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol (2003) 4.15
Excision margins in high-risk malignant melanoma. N Engl J Med (2004) 3.94
Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet (2009) 3.89
Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet (2008) 3.79
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov (2013) 3.71
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res (2010) 3.54
A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature (2011) 3.53
Genetic structure of Europeans: a view from the North-East. PLoS One (2009) 3.46
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2011) 3.43
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res (2006) 3.42
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
A single SNP in an evolutionary conserved region within intron 86 of the HERC2 gene determines human blue-brown eye color. Am J Hum Genet (2008) 3.00
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature (2011) 2.96
Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol (2009) 2.85
MC1R germline variants confer risk for BRAF-mutant melanoma. Science (2006) 2.84
The MC1R melanoma risk variant p.R160W is associated with Parkinson disease. Ann Neurol (2015) 2.71
Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst (2003) 2.70
Genome-wide association study identifies variants at 9p21 and 22q13 associated with development of cutaneous nevi. Nat Genet (2009) 2.65
Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments. J Cell Biol (2008) 2.61
MC1R, ASIP, and DNA repair in sporadic and familial melanoma in a Mediterranean population. J Natl Cancer Inst (2005) 2.57
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res (2008) 2.43
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 2.42
High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res (2006) 2.40
Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation. N Engl J Med (2014) 2.39
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet (2011) 2.36
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol (2011) 2.32
Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol (2009) 2.32
Genome-wide association study identifies three new melanoma susceptibility loci. Nat Genet (2011) 2.29
Genome-wide association study identifies novel loci predisposing to cutaneous melanoma. Hum Mol Genet (2011) 2.26
The Y deletion gr/gr and susceptibility to testicular germ cell tumor. Am J Hum Genet (2005) 2.26
Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer (2009) 2.26
Dermoscopy features of melanoma incognito: indications for biopsy. J Am Acad Dermatol (2006) 2.18
Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
A three-single-nucleotide polymorphism haplotype in intron 1 of OCA2 explains most human eye-color variation. Am J Hum Genet (2006) 2.14
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol (2013) 2.13
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother (2004) 2.12
Characterization of the Melanoma miRNAome by Deep Sequencing. PLoS One (2010) 2.08
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest (2009) 2.08
Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2012) 2.08
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Relationship between sunbed use and melanoma risk in a large case-control study in the United Kingdom. Int J Cancer (2011) 2.06
Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline--Update 2012. Eur J Cancer (2012) 2.05
Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer (2002) 2.02